| 丙型肝炎治疗新药替拉瑞韦 |
| |
| 引用本文： | 王莹莹,龚莉,王成港,王春龙.丙型肝炎治疗新药替拉瑞韦[J].药物评价研究,2011(6):482-486. |
| |
| 作者姓名： | 王莹莹 龚莉 王成港 王春龙 |
| |
| 作者单位： | 天津中医药大学;释药技术与药代动力学国家重点实验室;天津药物研究院 |
| |
| 摘 要： | 丙型肝炎病毒（hepatitis C virus,HCV）是一种高度变异的正链RNA黄病毒,具有慢性转化率高、病变率高等特征。有研究表明,NS3/NS4A多功能蛋白酶是HCV复制所必须的,因而NS3/NS4A蛋白酶抑制剂在HCV治疗中的意义备受关注。替拉瑞韦（Telaprevir）是一种可逆的HCVNS3/NS4A蛋白酶抑制剂,动物试验和临床试验都表明它可以有效地直接攻击HCV并阻断其复制,对HCV的抑制作用持久,将成为丙型肝炎病毒的新型治疗药物。
|
| 关 键 词： | 替拉瑞韦 丙型肝炎病毒 NS3/NS4A蛋白酶 蛋白酶抑制剂 1型丙型肝炎 |
Telaprevir used for treatment of hepatitis C |
| |
| WANG Ying-ying,GONG Li,WANG Cheng-gang,WANG Chun-long.Telaprevir used for treatment of hepatitis C[J].Drug Evaluation Research,2011(6):482-486. |
| |
| Authors: | WANG Ying-ying GONG Li WANG Cheng-gang WANG Chun-long |
| |
| Institution: | 2, 3 1. Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China 2. State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin 300193, China 3. Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China |
| |
| Abstract: | Hepatitis C virus （HCV） is a highly variable positive-strand RNA flavivirus, and has the characteristics of chronic high conversion and pathologic change. There are evidences shown that NS3/NS4A protease activity is essential for viral replication, thus the therapeutic significance of inhibiting the HCV protease NS3/NS4A has been widely concerned. Telaprevir, an ig administered, reversible, and peptidomimetic inhibitor of the HCV protease NS3/NS4A, has been proved to be effective for attacking HCV and breaking viral replication both in animal experiments and clinical trials. It is expected to become a new drug for treatment of HCV. |
| |
| Keywords: | Telaprevir hepatitis C virus （HCV） NS3/NS4A protease protease inhibitor hepatitis C 1 |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
